Background {#Sec1}
==========

Physicians are thought to play a critical role in the provision of smoking cessation assistance to patients \[[@CR1]\]. As more than 70% of smokers visit a physician annually \[[@CR2]\], medical practitioners are seen to have optimal opportunity to promote smoking cessation to their patients. Primary care practitioners in particular are visited on average more than 4 times per year by patients that smoke, and have thus been directed by clinical practice guidelines to identify and offer support to smokers at every visit. The Clinical Practice Guidelines for Treating Tobacco Use and Dependence, originally developed in 1996 by the United States Department of Human Health Services, stress that primary care physicians should treat tobacco dependence as a chronic disease and follow the 5A's model of: asking about smoking, assessing readiness to quit, advising smokers to stop, assisting patients with treatment, and arranging follow-up. These forms of intervention have been shown to be quite effective in motivating and driving smokers to quit, where even brief advice increases the odds of cessation \[[@CR3], [@CR4]\]. Combined behavioral counseling and pharmacotherapy however, has been shown to be the most effective at treating tobacco dependence, producing the highest odds of quitting and progressively higher quitting estimates with increased number of counseling sessions \[[@CR5]\].

Despite evidence showing that smoking cessation intervention in primary care is effective at helping smokers quit and offers a cost-effective option of reaching most smokers \[[@CR6]\], studies have shown that physicians have not been active in providing such assistance. Population-based surveys of smokers have revealed that between 44 and 71% were ever advised to quit, and even fewer received any form of intervention \[[@CR7]--[@CR9]\]. One telephone-based population survey had further documented that discussion about smoking was largely dependent on whether smokers were women, in the preparation stage of change, in fair or poor health, and smoked for a greater number of years \[[@CR9]\]. With follow-up care also arranged in less than 10% of all visits \[[@CR8], [@CR9]\], these practice gaps confirm findings from physician surveys that report physician behavior is below recommended guidelines \[[@CR10]--[@CR12]\].

To address such gaps, researchers have called for specific strategies aimed at enhancing the integration of clinical smoking cessation interventions into primary care settings. Some of these strategies include advanced training initiatives for physicians, enhanced use of established interventions, establishing performance feedback for practitioners, as well as the provision and combined use of low-cost or cost-free pharmacotherapy for patients \[[@CR10], [@CR13]\]. While several trials have evaluated the effectiveness of multi-component interventions in primary settings, to date, only one investigated the provision of cost-free medication. The trial revealed that the provision of cost-free nicotine replacement therapy (NRT) or bupropion in combination with general practitioner training strongly increases the odds of cessation (odds ratio of 4.77) and is markedly cost-effective in reducing smoking-related morbidity \[[@CR14], [@CR15]\]. As these findings suggest that smoking cessation support and provision of free pharmacotherapy in primary practice is an effective strategy of reducing smoking prevalence in the general population, cost-free medication provision appears to be an important component of achieving higher abstinence rates.

Over the past decade, many giveaway programs outside of clinical settings have provided NRT to large samples of smokers as part of a telephone quitline or large-scale distribution program. Studies evaluating these programs have generally revealed that compared to non-treatment cohorts, smokers receiving NRT were able to achieve higher quit rates, and that offering free NRT is an effective intervention in encouraging program participation, improves treatment satisfaction, and is cost-effective \[[@CR16]--[@CR20]\]. Direct causal evidence on the efficacy of large-scale distribution of free NRT has also been recently established, documenting that despite concerns over the 'real-world' effectiveness of NRT \[[@CR21], [@CR22]\], the mailed distribution of free nicotine patches in absence of behavioral support more than doubled the odds of cessation at a 6-month follow-up \[[@CR23]\]. Nonetheless, no previous studies had evaluated whether the provision of free NRT had promoted further help-seeking and what impact that interaction may have had. As mass distribution of NRT is being considered in many jurisdictions across the United States and Canada, it is important to identify whether this form of intervention drives smokers to seek out additional front-line support.

In the context of a randomized controlled trial evaluating the efficacy of mass distribution of free NRT to smokers, the aim of this study was to examine whether and to what extent the provision of free NRT impacts smokers' interaction with primary care physicians. In particular, the research attempted to answer the question: does the provision and subsequent use of free nicotine patches to smokers interested in quitting promote interaction with their primary care physicians, and whether that interaction has a role in quitting smoking?

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

A detailed research protocol of the overall trial design and primary outcomes are published elsewhere \[[@CR23], [@CR24]\]. Briefly, the trial employed a single blinded, panel survey design with random assignment to an experimental and a control group. Random digit dialing of Canadian telephone numbers and an initial interview was used to identify households with adult (age 18 or over) smokers who smoke 10 or more cigarettes per day. One individual from each household who was willing to take part in a smoking study that involved three interviews (baseline, 8-week and 6-month follow-ups) was randomly selected (according to most recent birthday). Of 43,785 households contacted, 2737 contained at least one adult daily smoker, and 2093 consenting individuals were interviewed (response rate of 76.5%) in English or French.

As part of the baseline survey, eligible participants (*n* = 1000) were identified and randomized into experimental and control groups to receive versus not receive free nicotine patches. Eligibility was determined by a series of questions regarding hypothetical interest in nicotine patches to quit smoking (including willingness to have nicotine patches sent to their home) and having no contraindications for using NRT. A randomized half of eligible participants were assigned to the experimental group and asked for their permission to have nicotine patches sent to their home. These participants were sent a package of 5 weeks of nicotine patches (tapered regimen of 3 weeks 21 mg patches, 1 week 14 mg patches, and 1 week 7 mg patches) to their homes via expedited postal mail to help them quit smoking. The package also contained a cover letter instructing them on the use of the patches, a list of answers to frequently asked questions, as well advice to talk to their physician or pharmacist if they had further questions. Participants in the control group were not offered nicotine patches or any other form of support, and were not aware that nicotine patches were offered to others.

Baseline and follow-up measures {#Sec4}
-------------------------------

All baseline and follow-up surveys were conducted by trained interviewers from the University of Waterloo Survey Research Centre. In addition to assessing eligibility for the randomized controlled trial, the baseline survey assessed participants' level of nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND) \[[@CR25]\], intent to quit using the Transtheoretical Model's stages of change (precontemplation, contemplation, and preparation stages) \[[@CR26], [@CR27]\], number and duration of past quit attempts, past use of NRT, motivation to quit smoking, a series of demographic characteristics, and the presence of a family practitioner. Those expressing intent to quit in the next 30 days and 6 months (preparation and contemplation stages, respectively) were further asked of their comfort in discussing smoking cessation with their primary care practitioner and whether they perceived their physician was aware of their interest in quitting.

Follow-up surveys conducted at both 8 weeks and 6 months post-baseline assessed smoking status, where abstinence at each of the follow-up periods was measured as positive endorsement of 'not smoking even a puff' for at least 7 days or 30 days, respectively. At 8 weeks, participants in the experimental group were asked if and how much of the nicotine patches sent to them were used (assessed using response options of "none", "some" and "all"), whether they had informed their physician of NRT use, their reasons for and against informing their physician, as well as having received additional support from their physician. Participants in the no-intervention control group were asked whether they had purchased and used any nicotine patches over-the-counter (OTC), had discussed smoking cessation with their physician post-baseline and the support, if any, they had received. At 6 months, all participants regardless of their randomly allocated group were asked if they had talked to their physician about smoking since they were last interviewed, whether they were encouraged by their practitioner to quit, and what forms of smoking cessation intervention were provided to them to help them quit. Discussion of smoking cessation with a primary care practitioner at 6 months post-baseline was the primary outcome measure.

Analyses {#Sec5}
--------

To investigate the impact of free NRT provision and use on physician interaction and smoking cessation, participants in the experimental group who endorsed using at least some of the provided nicotine patches by the 8 week follow-up (*n* = 246) were case matched to participants in the control group based on age, gender, severity of nicotine dependence, stages of change (precontemplation, contemplation, and preparation stages) and the completion of the 8 week follow-up survey. Both age and severity of nicotine dependence as determined by FTND were recoded into categorical values to facilitate optimal case matching. The age variable was recoded into five categories of 18--24, 25--34, 35--44, 45--54, and 55+, while FTND scores of 1 or 2 corresponded to low dependence, scores of 3 or 5 -- low to moderate dependence, scores of 5 to 7 -- moderate dependence, and scores of 8 to 10 -- high dependence. A total of 201 nicotine patch users were case matched to 201 no-intervention control participants.

Group differences in baseline demographic and smoking characteristics were evaluated using one-way analysis of variance (ANOVA) analyses for continuous variables and Pearson's chi-square tests of independence for categorical variables. In line with recommendations for outcomes analysis of matched case-control data \[[@CR28], [@CR29]\], McNemar's tests were used to evaluate differences in physician interaction at each follow-up, defined as discussing smoking with a physician. These analyses restricted the data to case-controlled pairs and were thus conducted only among those who were followed up and had a family physician at the respective follow-up (8 weeks: 177 matched pairs; 6 months: 155 matched pairs). Among specifically nicotine patch users in the experimental group, within group analyses further used chi square analyses to examine the impact of amount of nicotine patches used on physician interaction. To investigate the impact of physician interaction on cessation outcomes at 8 weeks and 6 months, separate univariate ANOVAs were conducted with group (experimental group nicotine patch users vs. control) as the between subjects factor, physician interaction at each follow-up as the within subjects factor, and making a serious quit attempt (defined as stopping smoking for 1 day or longer) and self-reported smoking abstinence (7-day point prevalence abstinence at 8 weeks and 30-day point-prevalence abstinence at 6 months) as the outcome measures. An intent-to-treat approach was employed for self-reported smoking abstinence, such that all participants lost to follow-up were assumed to be active smoking. All statistical analyses were conducted using IBM SPSS Statistics, version 24.0.

Results {#Sec6}
=======

Demographic characteristics {#Sec7}
---------------------------

Users of freely provided nicotine patches did not differ from case matched controls on any demographic or baseline smoking characteristics (*p* \> 0.05) (Table [1](#Tab1){ref-type="table"}). Both groups exhibited high follow-up rates, with 90.5% (*n* = 182) of nicotine patch users and 90.0% (*n* = 191) of controls re-interviewed at 6 months (*p* = 0.866).Table 1Demographic and smoking characteristics by groupRecipients and users of free nicotine patches (*n* = 201)^a^Control (*n* = 201)^a^*p*-valueDemographic Characteristics Age, mean (SD)49.6 (12.0)48.7 (11.2)0.446 Female, % (n)50.7 (102)50.7 (102)1.000 Married/Common-law, % (n)53.2 (107)59.7 (120)0.191 Employed full- or part- time, % (n)58.7 (118)62.2 (125)0.475 Education Level, % (n)0.440  Less than high school diploma24.0 (48)21.9 (44)  High school diploma38.0 (76)44.3 (89)  Post-secondary38.0 (76)33.8 (68) Household Income, % (n)0.940   \< \$60,00065.4 (125)65.1 (123)   ≥ \$60,00034.6 (66)34.9 (66) Health satisfaction, mean (SD)^b^3.2 (1.2)3.2 (1.1)0.764Smoking Characteristics Cigarettes/day, mean (SD)18.0 (7.2)17.9 (6.8)0.820 FTND score, mean (SD)5.0 (1.7)5.0 (1.8)0.822 Level of Nicotine Dependence, % (n)1.000  Low8.0 (16)8.0 (16)  Low to Moderate29.4 (59)29.4 (59)  Moderate56.2 (113)56.2 (113)  High6.5 (13)6.5 (13) Age at first smoking, mean (SD)14.4 (4.2)14.8 (3.8)0.307 Years as smoker, mean (SD)25.9 (13.3)24.2 (13.0)0.199 Number of previous quit attempts, % (n)0.142  05.0 (10)3.0 (6)  1--563.2 (127)72.1 (145)  6 +31.8 (64)24.9 (50) Past quit methods or aids used, % (n)  Nicotine replacement therapy (patch/gum/inhaler)68.6 (131)64.1 (125)0.351  Bupropion34.0 (65)31.3 (61)0.565  Varenicline33.0 (63)24.6 (48)0.069  Counselling (individual or group)7.3 (14)5.1 (10)0.370  Acupuncture/hypnosis/herbal remedies16.2 (31)16.4 (32)0.962  Self-help materials17.3 (33)17.9 (35)0.863 Stage of Change1.000  Precontemplation, % (n)20.4 (41)20.4 (41)  Contemplation, % (n)39.3 (73)39.3 (73)  Preparation, % (n)40.3 (81)40.3 (81) Confidence in ability to quit, mean (SD)5.8 (2.6)5.6 (2.4)0.428 Importance of quitting now, mean (SD)7.6 (2.2)7.7 (2.4)0.768 Comfort in discussing smoking cessation with family doctor, mean (SD)^c^8.5 (2.5)8.7 (2.3)0.623Note: SD = standard deviation; FTND = Fagerström Test for Nicotine DependenceAge, Gender, FTND, and Stage of Change were used to case match control participants to recipients and users of nicotine patches in the experimental group^a^Sample sizes vary due to missing data on some variables^b^Health satisfaction was assessed by way of the World Health Organization Quality of Life Instrument (WHOQOL-BREF) \[[@CR42]\] question on health satisfaction over the past 2 weeks, where participants were asked to rate how satisfied they are with their health on a 5-point Likert scale of 1 (very dissatisfied) to 5 (very satisfied)^c^Comfort in discussing smoking cessation with family doctor was assessed on a Likert scale of 1 (not at all comfortable) to 10 (very comfortable). This question was asked only of those in the preparation and contemplation stages of change

At baseline, individuals in the preparation and contemplation stages of change (*n* = 320) were asked whether they thought their doctor was aware of their interest in quitting smoking. Of this subgroup, 88.1% (*n* = 141) of eventual nicotine patch recipients and 90.0% (*n* = 144) of those in the control group had a family physician. Across both groups, three quarters (75.1%) had endorsed that their family doctor was aware, and of those, an average of 87.7% reported that their doctor encouraged them to quit. No differences in rates were noted between groups.

Physician interaction {#Sec8}
---------------------

Among those with a family physician at the 8 week follow-up (*n* = 177 per group; 88% of entire sample), 26.0% of nicotine patch users had informed their physician they had started using their nicotine patches, while 25.4% of control participants had talked to their doctor about smoking (*p* = 1.00). At the 6 month follow-up, among those contacted with a family physician (*n* = 155 per group; 77% of entire sample), nicotine patch users reported greater frequency of discussing smoking with their physician (43.9%), as compared to the control group (30.3%) (*p* = 0.011).

Of nicotine patch users at 8 weeks, 82.1% (*n* = 165) reported to have used some but not all of the nicotine patches provided and 17.9% (*n* = 36) reported to have used all the patches. No differences in physician interaction were observed between those who used all or just some of the provided nicotine patches at both 8 weeks (χ^2^ = 0.96, *p* = 0.327) and 6 month follow-ups (χ^2^ = 0.91, *p* = 0.341).

Nicotine patch users' reasons for and against informing physicians of patch initiation {#Sec9}
--------------------------------------------------------------------------------------

Among individuals in the experimental group, reasons for informing a physician of nicotine patch use were evaluated at the 8 week follow-up (*n* = 48). While a large majority (62.5%) informed their physician of nicotine patch use as part of a visit for an unrelated issue, 39.6% had sought additional support, 18.8% felt obligated, 12.5% had concerns about possible interactions between the patches and other medication or health conditions, 8.3% were advised by a friend or family member, and 8.3% for other reasons. Among nicotine patch users who had not informed their physician at 8 weeks of their nicotine patch use (*n* = 133) on the other hand, the top rated reason for not informing a physician of nicotine patch use was that they did not think they should have or needed to (56.2%). Other reasons were that it is time consuming to visit a doctor (52.6%), smoking is not a serious medical problem (27.8%), felt they could quit without physician help (26.3%), did not want to use prescription drugs (24.8%), have not seen a doctor (13.5%), believed that doctors can't help quit smoking (11.3%), and other (15.8%). Separately, reasons for and against informing a family physician of nicotine patch use were not mutually exclusive.

Physician assistance offered {#Sec10}
----------------------------

Of participants who used the freely provided nicotine patches and informed their physician of doing so by the 8 week follow-up (*n* = 48), 39.8% were offered additional support by way of a prescription for varenicline or bupropion, 35.4% were given a brief intervention in the form of a smokers helpline number or pamphlet, 25% were provided with or offered counselling, 18.8% were encouraged to use nicotine gum or inhaler, and 31.3% received none of the above.

Of participants in the control group who had talked about smoking with their doctor by the 8 week follow-up (*n* = 48), 83.3% (*n* = 40) were encouraged to quit. Of these, 50% were offered varenicline or bupropion, 42.5% were given a brief intervention in the form of a smokers' helpline number or pamphlet, 32.5% were encouraged to use NRT (nicotine patch, gum or inhaler), 15% received or were referred to counselling, and 22.9% received none of the above.

At the 6 month follow-up, 91.8% (*n* = 67) of nicotine patch users and 92.5% of (*n* = 49) of controls who had talked to their family physician about smoking reported they had been encouraged to quit. Figure [1](#Fig1){ref-type="fig"} depicts proportions of assistance offered by group among those who have talked to their physician about smoking.Fig. 1Physician assistance offered between 8 week and 6 month follow-ups. Note: NP, nicotine patch

Impact of physician interaction on smoking cessation {#Sec11}
----------------------------------------------------

Separate univariate ANOVA tests were conducted to evaluate the effect of group, physician interaction and physician interaction by group on quitting smoking at both 8 weeks (7-day point prevalence abstinence) and 6 months (30-day point prevalence abstinence) and making a serious quit attempt (quitting for 1 day or longer), using an intent to treat approach (Table [2](#Tab2){ref-type="table"}). A main effect of Group was evident for abstinence and making a serious quit attempt at both follow-up periods, such that nicotine patch users exhibited greater cessation rates and serious quit attempts compared to case matched controls. A significant interaction effect between group and physician interaction was observed for making a serious quit attempt at 6 month follow-up. Post-hoc analyses revealed that this interaction effect was driven by two observations: a) nicotine patch users who had discussed cessation with a physician had made serious quit attempts at significantly greater rates (72.6%), compared to controls (49.1%) (χ^2^ = 7.28, *p* = 0.007); and b) within the control group, frequency of making serious quit attempts was higher among those that discussed smoking cessation with a physician at 6 month follow-up (49.1%), compared to those who did not speak with a physician (24.4%) (χ^2^ = 10.39, *p* = 0.001).Table 2Impact of physician interaction on quitting smokingAbstinence (7-day pp)Serious Quit Attempt8-week Follow-upF*p*-valueF*p*-value Main effect of Group5.690.018160.11\<0.001 Main effect of Physician Interaction1.930.1651.970.161 Interaction between Group and Physician Interaction2.960.0860.4420.506Abstinence (30-day pp)Serious Quit Attempt6-month Follow-upF*p*-valueF*p*-value Main effect of Group3.990.04759.92\<0.001 Main effect of Physician Interaction0.290.5943.740.054 Interaction between Group and Physician Interaction0.770.3824.140.003

Evaluating quitters at 6 months (using 30 day abstinence point prevalence), no differences were observed between the two groups in physician interaction throughout the study, such that 45% (*n* = 9) of abstainers in the nicotine patch use group had talked to their doctor at any point throughout the study, compared to 62.5% (*n* = 5) of those in the control group (Fisher's Exact Test, *p* = 0.678).

Discussion {#Sec12}
==========

To our knowledge, this is the only intervention study to date to evaluate the impact of free (to the end user) NRT provision on further help seeking and its associated smoking cessation implications. The study identified that while smokers are generally comfortable in turning to their primary care physicians for smoking-related support, most participants, regardless of whether they received and used nicotine patches, did not discuss cessation with their physician by either the 8 week or 6 month follow-ups. Among nicotine patch users at the 8 week follow-up, predominant reasons for not seeking support were beliefs that they did not need to visit a physician, it is time consuming to do so, and the perception that smoking is not a serious medical problem. Such reluctance to proactive support seeking suggests that most smokers generally hold passive views towards primary care physicians' role in smoking cessation when considering or initiating quitting. Other research has also documented that while some reluctance to consult a practitioner stems from individuals not seeing smoking as an illness \[[@CR30], [@CR31]\], others do not seek physician support due to the perception that they have little to offer or the belief that smoking is not a condition that requires medical help \[[@CR32]\].

Of those that did visit their physician however, an overwhelming majority reported that their doctors were active in encouraging them to quit. Again, regardless of whether smokers had received and used free nicotine patches, between 83% and 93% of those that discussed smoking cessation with their doctor throughout the 6 month duration of the study were advised to quit, and over 70% were offered additional or alternative support. While the provision and use of nicotine patches, and possibly just surveying about smoking habits, may aid in stimulating patient-initiated discussion of smoking cessation with primary care physicians, these findings point to an encouraging trend of greater physician compliance with the *advise* and *assist* components of the 5A model, as seen in recent representative U.S. population surveys \[[@CR33], [@CR34]\]. They may also be indicative of a shift in practice guideline adherence among specifically Canadian physicians, which were reported in 2012 to offer advice to quit to merely 56% of smokers who had visited them in the past year, and fewer than 30% of surveyed smokers received information about assistance \[[@CR35]\]. As recipients and users of nicotine patches in the current study were more likely to discuss smoking with their physicians compared to the no intervention control group, the findings suggest that the provision of free NRT particularly to those who are likely to use it may facilitate opportunities for benefits beyond the direct pharmacological effects of the medication, such as the receipt of physician-assisted brief or supplementary intervention. Indeed, nicotine patch users who had discussed cessation with a physician between the 8 week and 6 month follow-ups were more likely to make a serious quit attempt compared to controls. From a public health perspective, the mailed out provision of free nicotine patches may therefore be effective in not only promoting cessation but also in stimulating conversations and support from health professionals that help towards achieving that goal.

It is important to note that approximately 70% of participants who had used the freely provided nicotine patches by 8 weeks and informed their physicians of doing so, were provided with supplementary support, the most common being prescribed varenicline or bupropion. The majority (73.7%) of nicotine patch users had used only some of the provided NRT, therefore it is most likely that the medications were prescribed subsequent to their discontinuation of nicotine patches. The remaining 26.3% however, reported to have used all their nicotine patches by 8 weeks, in which case it is plausible to suspect that these participants were prescribed the medications while they were still using the nicotine patches, contrary to the recommendations of the National Institute for Health and Care Excellence (NICE) \[[@CR36]\] and US Public Health Clinical Practice Guidelines for Treating Tobacco Use and Dependence (for varenicline only) \[[@CR37]\]. Nearly one half (45.5%) of those who used all their nicotine patches and informed their physician of doing so were prescribed varenicline or bupropion. The combination of bupropion and NRT has been reported to provide similar benefit as either therapy alone \[[@CR38]\], and only until a recent systematic review and meta-analysis \[[@CR39]\], combination therapy of varenicline and NRT produced favorable, albeit non-significant effects on cessation \[[@CR40], [@CR41]\]. However, in the event that the prescribed cessation medications were utilized, it is unclear what role, if any, that would have had on the observed effects in this study. Further research is necessary to evaluate the effectiveness of combination therapy on cessation outcomes in primary care settings, as well as directly contrast the effectiveness of nicotine patches and combination nicotine patch and varenicline in an open label design.

Several limitations of the current study should be noted. First, as nicotine patch users in the experimental group were asked specifically whether they had informed their physician of patch use at 8 weeks, as opposed to whether they had discussed smoking cessation with their physician, direct comparisons between this group of smokers and control participants could not be made. Second, as we were intent on examining how the receipt and specifically use of free nicotine patches is associated with physician interaction, thus necessitating case control matching, the employed random assignment to condition was compromised and placed limits on our ability to infer causality of intervention. Third, the temporal order of nicotine patch use and physician interaction was not captured, therefore nicotine patch use could have either preceded and caused participants to visit their physician (whether due to side effects or additional support), or some participants may have sought physician advice prior to initiating patch use. It is therefore important to emphasize again that the present findings pertain specifically to an association between use of freely provided nicotine patches and physician support, and are not causal in any regard. Third, recipients of the 5 week course of nicotine patches were advised to talk to their physician or pharmacist if they had additional questions to the included instructions on how to use the patches, in compliance with common pharmacotherapy distribution practices and our research ethics board recommendations. Some individuals however, may have perceived this as direct instructions to seek out physician support. Fourth, asking whether participants had visited a physician and discussed smoking cessation could have been subject to recall bias. Finally, biochemical verification of smoking status could not be effectively executed \[[@CR23]\], therefore cessation outcomes are based on self-report data.

Conclusions {#Sec13}
===========

Use of freely distributed nicotine patches promoted further smoking cessation centered discussion with family physicians, compared to non-recipients of NRT. Although this was associated with increased likelihood of making a quit attempt, nicotine patch users as a whole generally did not turn to their physicians for cessation assistance, expressing reluctance in seeking their support. In line with grater adherence to clinical practice guidelines of following the 5A model, promotion of physician capacity in addressing tobacco dependence with patients could be enhanced through non-judgmental, stage-based brief motivational interviewing methods. Future research is warranted to examine whether the free NRT distribution as part of smokers' helplines also mobilizes additional health-care provider support, in particular among pharmacists, who are generally more easily accessible than physicians.
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